CytoDyn, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cytodyn.com
Clinical Trials
24
Active:1
Completed:10
Trial Phases
2 Phases
Phase 1:3
Phase 2:18
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Phase 2
18 (85.7%)Phase 1
3 (14.3%)A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06699836
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- CCR5Microsatellite StableMetastaticColorectal Cancer
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT05730673
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Phase 2
- Conditions
- HIV-1-infection
- Interventions
- Drug: PRO 140 700Drug: PRO 140 350Drug: PRO 140 525
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05271370
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Phase 2
Completed
- Conditions
- Coronavirus Disease 2019
- Interventions
- Drug: Placebos
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04678830
- Locations
- 🇺🇸
Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
🇺🇸Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Phase 2
Completed
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04521114
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Meridien Research, Maitland, Florida, United States
🇺🇸Floridian Clinical Research, Miami Lakes, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found